RPL5

Large ribosomal subunit protein uL18 · P46777 · RPL5 on Sugi Atlas →

3,671 patent compounds predicted against RPL5, 1,923 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors	PHASE2	RECRUITING
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE2	NOT_YET_RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Modulate Cellular Stress in the Immune Cells to Reduce Rate of Symptomatic Viral Infection	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Clinical Study of Therapeutic Immunological Agent for EBV-positive Advanced Malignant Tumors	PHASE1	ACTIVE_NOT_RECRUITING
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Phase I Safety and Immunogenicity Preventative Vaccine Trial Based on Recombinant Tat Protein	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Esophageal Cancer	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma	nan	WITHDRAWN
Mobilization of CD34+ Peripheral Blood Stem Cells in Patients With Diamond Blackfan Anemia Syndrome (DBAS)	nan	RECRUITING
Pharmacogenomics of Interferon and Ribavirin Treatment in Patients With Chronic Hepatitis C Virus Infection	nan	UNKNOWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Epidemiologic, Clinical and Molecular Characteristics of Patients With Acute Respiratory Failure Affected by 2019-NCOV.	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a RPL5 binder may also engage these)

Protein	Name	Similarity
Q4R5M0	—	1.000	Q4R5M0 →
P09895	—	1.000	P09895 →
Q58DW5	—	1.000	Q58DW5 →
P15125	—	1.000	P15125 →
P22451	—	1.000	P22451 →
Q56FG6	—	1.000	Q56FG6 →
Q9W5R8	—	1.000	Q9W5R8 →
Q6UNT2	—	1.000	Q6UNT2 →
O76190	—	1.000	O76190 →
P26321	—	1.000	P26321 →
Q4KTI3	—	1.000	Q4KTI3 →
P19949	—	0.999	P19949 →
P47962	—	0.999	P47962 →
Q5XUC7	—	0.999	Q5XUC7 →
G0SEG2	—	0.998	G0SEG2 →
O65353	—	0.998	O65353 →
P15126	—	0.998	P15126 →
Q1HQU2	—	0.997	Q1HQU2 →
Q5EY89	—	0.997	Q5EY89 →
Q54XX3	—	0.997	Q54XX3 →
Q8LBI1	—	0.996	Q8LBI1 →
P49227	—	0.995	P49227 →
A2WXX3	—	0.994	A2WXX3 →
Q4N655	—	0.994	Q4N655 →
Q26481	—	0.993	Q26481 →
Q6JWW5	—	0.993	Q6JWW5 →
O59953	—	0.993	O59953 →
Q627R7	—	0.991	Q627R7 →
Q8L4L4	—	0.991	Q8L4L4 →
Q231U7	—	0.991	Q231U7 →